Why It Matters
The Animal Health Institute (AHI) faces urgent challenges from foreign animal disease threats and regulatory pressures requiring immediate federal action. Highly Pathogenic Avian Influenza and New World Screwworm outbreaks have intensified demands for expanded appropriations, expedited drug approvals, and strengthened surveillance.
Without adequate federal funding and streamlined FDA pathways, the industry argues it cannot respond quickly to evolving threats. Trade volatility and antimicrobial resistance scrutiny add complexity, forcing AHI to simultaneously defend market access and demonstrate stewardship.
By the Numbers
The Animal Health Institute spent $50,000 on in-house lobbying in final quarter 2025, conducted by veterans Ronald B. Phillips and Virginia Sessions Siller.
AHI is a veteran lobbying player with 168 total disclosures since 2003. Phillips has lobbied for AHI since 2003, appearing on 77 disclosures totaling $2.54 million. Siller joined in 2023, focusing on trade, appropriations, and animal drug regulations. AHI augments internal efforts with external firms, including Torrey Advisory Group ($840,000 since 2020).
Budget appropriations for USDA and FDA appear most frequently across historical filings (77 instances), followed by trade matters (44 instances) and pharmaceutical policy issues (33 instances each).
The Agenda
AHI is lobbying on four major policy areas. The organization pushes for FDA regulatory modernization on animal drug approvals, compounding rules, and antimicrobial resistance reporting. It advocates for FY2026 appropriations to USDA, FDA, and EPA—agencies critical to animal health programs.
On agriculture, AHI presses lawmakers on disease preparedness, specifically HPAI and New World Screwworm response efforts. The organization engages on international trade issues, including tariffs and U.S. participation in international food standards through Codex.
Broader Context
The ongoing HPAI outbreak has spread to livestock, prompting legislation like the Foreign Animal Disease Prevention Act. USDA announced a multi-hundred-million-dollar screwworm containment strategy in August 2025.
The FDA is modernizing drug approval processes, phasing out animal testing requirements and expediting reviews. Antimicrobial resistance faces intense scrutiny, with lawmakers pushing stricter stewardship standards.
Appropriations debates for fiscal 2026 are underway, with the House Appropriations Subcommittee markup determining funding for USDA and FDA animal health programs.
Between The Lines
Congress actively advances legislation aligned with AHI priorities. Lawmakers introduced the Foreign Animal Disease Prevention Act and New World Screwworm Preparedness Act, authorizing substantial federal spending. A House Agriculture Subcommittee hearing examined the National Animal Health Laboratory Network’s role against HPAI and Screwworm threats.
The Pet Food Uniform Regulatory Reform Act seeks to streamline FDA’s veterinary medicine framework. The Safe American Food Exports Act would help maintain U.S. animal product exports during outbreaks.
Competitive Landscape
The American Veterinary Medical Association pursues overlapping goals, focusing on veterinary workforce expansion and appropriations for USDA/FDA programs.
While AVMA and AHI interests frequently align on disease prevention and federal funding, they diverge on drug compounding and professional scope. AVMA’s workforce development efforts, like the Senate Veterinary Medicine Caucus, complement AHI’s manufacturer-centric agenda.
The Bottom Line
AHI’s $50,000 final quarter 2025 lobbying focused on FDA veterinary regulations, FY2026 appropriations, and disease response. The organization’s 168 disclosures since 2003 position it as a consistent industry voice on congressional priorities: foreign animal disease preparedness, FDA modernization, and trade policy.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article